CHINA INSIDER: WHAT WENT WRONG AND HAS ANYTHING CHANGED?
strategy Several years have past since tainted crude heparin made its way into the US and other foreign healthcare systems. While over 170 people died and many more were sickened by using commercial...
View ArticleTHE EVOLVING LEGAL PATHWAYS FOR BIOSIMILARS IN THE UNITED STATES
biosimilar $54 billion worth of patents covering biological products will expire in the United States before 2020, including patents covering the blockbuster monoclonal antibody therapeutics Herceptin®...
View ArticleBEST INDICATORS OF CLINICAL DEVELOPMENT SUCCESS
strategy Tom Macek PharmD, PhD, Director, Clinical Sciences, Takeda Global Research and Development; speaker at the Marcus Evans Evolution Summit 2012, on successful clinical development. “In clinical...
View ArticleENTERING NEW MARKETS
strategy A Macroeconomic Summary of the Issue Abstract: The model used to research, develop and manufacture life-saving drugs can no longer support the needs of a massive, mobile and emerging global...
View ArticlePHARMA 3.0: FOLLOWING THE PROGRESS OF AN INDUSTRY ADAPTING ITSELF FOR BIG CHANGE
strategy Although most of “Big Pharma” is still preparing itself for Pharma 2.0 in diversifying sales, reshaping their research and development, and expanding their business to developing countries,...
View ArticleAN INTEGRATED APPROACH TO BIOSIMILAR DEVELOPMENT & COMMERCIALIZATION
biosimilar Leverage smart simulation applications from high-tech companies for manufacturing Over the next 10– 15 years, the biosimilars industry is expected to explode as the patents on branded...
View ArticleTHIS WEEK’S PREMIUM COLLECTION: BIOSIMILARS
biosimilar There is enormous opportunities ahead for the Biosimilars industry. This special magazine collection explores the trends, opportunities, challenges, obstacles and legalities facing the...
View ArticleTHIS WEEK’S PREMIUM COLLECTION: EMERGING MARKETS
emerging markets Are you considering new markets, curious about doing business in China? What about the growing market of Brazil? Check out this weeks premium collection as we explore some key emerging...
View ArticleWill Biosimilars Break Into The Market
In 2006, the biopharmaceutical firm, Biopartners, made an impressive improvement to the administration of a growth hormone injection. The new drug, while maintaining the same benefits, now only has...
View ArticleBIOSIMILARS AND STATE LEGISLATION
law Despite the fact that no biosimilars have actually reached the US market yet, debates about their use and substitution have been rumbling about since the first approach of patent expiries for...
View Article
